Grant Detail
The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.
AMEYLOID VACCINE, AMYLOID REMOVAL MECHANISMS AND SYNAPTI
30 September 2001 - 31 August 2007
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Total Funding: $ 1,285,000
Published data show that beta amyloid vaccination can markedly reduce amyloid burdens, apparently by activating microglia to degrade amyloid. Vaccinations may also prevent certain behavioral deficits. The overall impact on the AD phenotype remains vague. Vaccination might be expected to reduce amyloid but activate microglial inflammatory cytokine production, NADPH oxidase and reactive oxygen species. This may lead to a net decrease or possibly even an increase in oxidative damage and synapse loss. In this proposal, Aim 1 will address unanswered questions about the impact of vaccination at different timepoints on aspects of inflammation while aim 2 will investigate the impact on oxidative damage and synaptic pathology that we have documented in aging APP transgenic mice. Present data suggests that vaccination may not reduce Abeta 40 and vascular amyloid. There is also a real danger that vaccination may induce vascular damage and possibly even hemorrhage. Aim 3 will assess the impact of vaccination on amyloid and soluble Abeta in different compartments, vascular amyloid and vessel damage. Finally, there are unanswered questions about the mechanisms of amyloid reduction induced by vaccination. Available data strongly support an increase in amyloid phagocytosis by microglia, but data on enhanced degradation are inconsistent with some reports showing increases and some showing no change in amyloid degradation. Aim 4 will investigate hypotheses about the mechanisms involved in vaccine induced amyloid reductions. If successful, these experiments would be expected to lead to small molecule approaches to mitigate potential harmful effects of vaccination and to conceivably enhance amyloid removal.
11 Resulting Publications
-
1.
2008Jeffrey A Fein; Sophie Sokolow; Carol A Miller; Harry V Vinters; Fusheng Yang; Gregory M Cole; Karen Hoppens Gylys
Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.
The American journal of pathology 2008;172(6):1683-92. -
2.
2007Qiu-Lan Ma; Marni E Harris-White; Oliver J Ubeda; Mychica Simmons; Walter Beech; Giselle P Lim; Bruce Teter; Sally A Frautschy; Greg M Cole
Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models.
Journal of neurochemistry 2007;103(4):1594-607. -
3.
2006Qiu-Lan Ma; Giselle P Lim; Marni E Harris-White; Fusheng Yang; Surendra S Ambegaokar; Oliver J Ubeda; Charles G Glabe; Bruce Teter; Sally A Frautschy; Greg M Cole
Journal of neuroscience research 2006;83(3):374-84. -
4.
2006Lixia Zhao; Qiu-Lan Ma; Frédéric Calon; Marni E Harris-White; Fusheng Yang; Giselle P Lim; Takashi Morihara; Oliver J Ubeda; Surendra Ambegaokar; James E Hansen; et al.
Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease.
Nature neuroscience 2006;9(2):234-42. -
5.
2005Greg M Cole; Giselle P Lim; Fusheng Yang; Bruce Teter; Aynun Begum; Qiulan Ma; Marni E Harris-White; Sally A Frautschy
Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions.
Neurobiology of aging 2005;26 Suppl 1():133-6. -
6.
2005Frédéric Calon; Giselle P Lim; Takashi Morihara; Fusheng Yang; Oliver Ubeda; Norman Salem; Sally A Frautschy; Greg M Cole
The European journal of neuroscience 2005;22(3):617-26. -
7.
2005Takashi Morihara; Bruce Teter; Fusheng Yang; Giselle P Lim; Sally Boudinot; F Douglas Boudinot; Sally A Frautschy; Greg M Cole
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(6):1111-20. -
8.
2005John M Ringman; Sally A Frautschy; Gregory M Cole; Donna L Masterman; Jeffrey L Cummings
A potential role of the curry spice curcumin in Alzheimer's disease.
Current Alzheimer research 2005;2(2):131-6. -
9.
2005Fusheng Yang; Giselle P Lim; Aynun N Begum; Oliver J Ubeda; Mychica R Simmons; Surendra S Ambegaokar; Pingping P Chen; Rakez Kayed; Charles G Glabe; Sally A Frautschy; et al.
The Journal of biological chemistry 2005;280(7):5892-901. -
10.
2004Greg M Cole; Takashi Morihara; Giselle P Lim; Fusheng Yang; Aynun Begum; Sally A Frautschy
NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models.
Annals of the New York Academy of Sciences 2004;1035():68-84. -
11.
2004Frédéric Calon; Giselle P Lim; Fusheng Yang; Takashi Morihara; Bruce Teter; Oliver Ubeda; Phillippe Rostaing; Antoine Triller; Norman Salem; Karen H Ashe; et al.
Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model.
Neuron 2004;43(5):633-45.
Scientific Context
This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.
Related Grants
-
1.
Golde, Todd E
In situ therapeutic anti-AB delivery/adenoviral vectors
1 September 2002 - 31 August 2006
NATIONAL INSTITUTE ON AGING
Total Funding: $ 706,819
-
2.
Davies, Peter P
Aging and Dementia: Cholinergic neuron biochemistry
1 March 2006 - 28 February 2011
NATIONAL INSTITUTE OF MENTAL HEALTH
Total Funding: $ 4,531,594
-
3.
Cole, Gregory M
Can Omega 3 fatty acids Slow Alzheimer Pathogensis?
1 September 2005 - 31 August 2009
NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE
Total Funding: $ 1,072,290
Related Publications
-
1.
2013Sang-Ho Choi; Saba Aid; Luca Caracciolo; S Sakura Minami; Takako Niikura; Yasuji Matsuoka; R Scott Turner; Mark P Mattson; Francesca Bosetti
Journal of neurochemistry 2013;124(1):59-68. -
2.
2003Mark P Mattson; Sic L Chan
Good and bad amyloid antibodies.
Science (New York, N.Y.) 2003;301(5641):1847-9. -
3.
2002Dale Schenk
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning.
Nature reviews. Neuroscience 2002;3(10):824-8.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
411









-
505









-
779









-
571









-
377









-
610











